hIL-13-PE38QQR. NeoPharm

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• NeoPharm is developing a novel antitumor agent, IL-13-PE38QQR, a fusion molecule combining human IL-13 with a Pseudomonas exotoxin (PE38QQR).
• This agent is licensed from the NIH and FDA, indicating significant preclinical validation and regulatory oversight.
• The molecule targets specific receptors, offering a targeted approach to cancer therapy.

Purpose of the Study:

• To evaluate the safety and efficacy of IL-13-PE38QQR as an antitumor agent.
• To investigate its potential in treating specific cancers like renal cell carcinoma (RCC) and glioblastoma.
• To initiate clinical trials and assess patient response to this novel therapeutic.

Main Methods:

• Investigational New Drug (IND) applications were filed for RCC and glioma in 1999, and for glioblastoma in 2000.
• Phase I/II clinical trials were initiated in December 2000 for patients with refractory glioblastoma multiforme.
• Phase I trials for RCC treatment commenced in October 1999.

Main Results:

• The first patient with brain cancer completed treatment with IL-13-PE38QQR.
• Clinical trials are actively enrolling and progressing for both glioblastoma and RCC.
• The potential US market for hIL-13-PE38QQR was estimated at $5.8 billion in February 2000.

Conclusions:

• IL-13-PE38QQR represents a promising therapeutic candidate for challenging cancers.
• Ongoing clinical trials are crucial for determining its definitive role in cancer treatment.
• The substantial market potential underscores the anticipated clinical need for such therapies.